|
|
Article: Amicus Series B Garners $31M For Oral Fabry's Small Molecule.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Wading into the turbulent waters of treatments for lysosomal storage disorders - in which other companies have clashed over patent holdings - Amicus Therapeutics Inc. raised $31 million in a Series B financing to advance its candidate for Fabry's disease to the clinic.
But New Brunswick, N.J.-based Amicus has reason to expect smoother sailing for its Fabry's disease therapy. Unlike other therapies for the disease, which aim to replace the alpha-galactosidase A enzyme that Fabry's patients lack, Amicus' AT1001 is a small-molecule, oral drug to enhance the patient's own enzyme activity.
The money gives New Brunswick, N.J.-based ...
Related newspaper, magazine, and journal articles:
|
|
Article: Global Partners LP Signs Agreement to Acquire ...
Business Wire;
August 6, 2009 ;
700+ words
... ... Southeastern New York WALTHAM, Mass. -- Global Partners LP (NYSE:GLP), a leading wholesale supplier ... based in Providence, Rhode Island. About Global Partners LP Global Partners LP, a publicly traded master limited partnership ...
|
|